Determinants of TB control, relapse and reinfection

结核病控制、复发和再感染的决定因素

基本信息

  • 批准号:
    10621299
  • 负责人:
  • 金额:
    $ 256.5万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2021
  • 资助国家:
    美国
  • 起止时间:
    2021-07-01 至 2026-04-30
  • 项目状态:
    未结题

项目摘要

Mycobacterium tuberculosis (Mtb), the causative agent of tuberculosis (TB), continues to be a severe global health problem. TB is multifaceted, but a central clinical and microbiologic feature of the disease is the ability of Mtb to resist complete elimination, both by the host immune system and by chemotherapeutic agents with potent growth inhibitory activity. This persistence in the face of immunologic and antibiotic pressure underlies several important facets of TB disease, including 1) the existence of latent tuberculosis infection (LTBI) and, in the setting of immunologic failure of LTBI control, its role in the genesis of active TB and 2) the prolonged course of TB antibiotic therapy, which requires 6 months of multidrug therapy to achieve reliable clinical cure. Rather than producing complete bacterial eradication in all treated subjects, cure following TB chemotherapy is now understood to be an antibiotic induced paucibacillary state in which prevention of relapse depends in part on poorly understood host factors. The host and bacterial determinants that mediate these two interrelated types of persistence are only partially understood, a knowledge gap the Tri-I-TBRU aims to fill. We propose a set of 3 intersecting projects and 3 cores all focused on different facets of the problem of paucibacillary TB, both post treatment and LTBI. The projects will use samples and clinical data from TB cohorts at our clinical site at GHESKIO in Port Au Prince Haiti, to examine the immunologic, microbiomic, transcriptomic, pharmacokinetic, and genetic factors that influence or predict the transition points between paucibacillary states of TB disease and active transmissible infection. These human studies will be compared and contrasted with a new mouse model of paucibacillary infection that will allow us to test mechanistic hypotheses about the host and bacterial determinants of paucibacillary disease. This work with be conducted by a team of highly collaborative investigators who have who have worked well together for several years.
结核分枝杆菌(Mycobacterium tuberculosis,Mtb),结核病(TB)的病原体,仍然是严重的全球性结核病。 健康问题。结核病是多方面的,但该疾病的中心临床和微生物学特征是能够 结核分枝杆菌抵抗完全消除,无论是由宿主免疫系统和化疗剂与有效的 生长抑制活性面对免疫和抗生素的压力,这种坚持是几个 结核病的重要方面,包括1)潜伏性结核感染(LTBI)的存在, LTBI控制的免疫失败,其在活动性TB的发生中的作用和2)TB的病程延长 抗生素治疗,需要6个月的多药治疗才能实现可靠的临床治愈。而不是 在所有接受治疗的受试者中产生完全的细菌根除, 被理解为抗生素诱导的少菌状态,其中复发的预防部分依赖于 对宿主因素知之甚少。介导这两种相互关联的类型的宿主和细菌决定簇 持久性只是部分理解,这是Tri-I-TBRU旨在填补的知识空白。我们建议一套3 交叉项目和3个核心项目都侧重于少杆菌结核病问题的不同方面, 治疗和LTBI。这些项目将使用来自我们临床研究中心的结核病队列的样本和临床数据, 海地Au Prince港的GHESKIO,检查免疫学,微生物组学,转录组学,药代动力学, 以及影响或预测结核病的少菌状态之间的转变点的遗传因素, 活动性传染病这些人类研究将与一种新的小鼠模型进行比较和对比 这将使我们能够测试关于宿主和细菌的机制假设, 少杆菌病的决定因素。这项工作将由一个高度协作的团队进行 几年来一直合作得很好的调查人员。

项目成果

期刊论文数量(7)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
Inborn errors of human transcription factors governing IFN-γ antimycobacterial immunity.
控制 IFN-γ 抗分枝杆菌免疫的人类转录因子的先天性错误。
  • DOI:
    10.1016/j.coi.2023.102296
  • 发表时间:
    2023
  • 期刊:
  • 影响因子:
    7
  • 作者:
    Ogishi,Masato;Yang,Rui;Rosain,Jérémie;Bustamante,Jacinta;Casanova,Jean-Laurent;Boisson-Dupuis,Stéphanie
  • 通讯作者:
    Boisson-Dupuis,Stéphanie
Genome-wide detection of human intronic AG-gain variants located between splicing branchpoints and canonical splice acceptor sites.
  • DOI:
    10.1073/pnas.2314225120
  • 发表时间:
    2023-11-14
  • 期刊:
  • 影响因子:
    11.1
  • 作者:
    Zhang, Peng;Chaldebas, Matthieu;Ogishi, Masato;Al Qureshah, Fahd;Ponsin, Khoren;Feng, Yi;Rinchai, Darawan;Milisavljevic, Baptiste;Han, Ji Eun;Moncada-Velez, Marcela;Keles, Sevgi;Schroeder, Bernd;Stenson, Peter D.;Cooper, David N.;Cobat, Aurelie;Boisson, Bertrand;Zhang, Qian;Boisson-Dupuis, Stephanie;Abel, Laurent;Casanova, Jean- Laurent
  • 通讯作者:
    Casanova, Jean- Laurent
Inherited human ITK deficiency impairs IFN-γ immunity and underlies tuberculosis.
Mycobacterium tuberculosis resisters despite HIV exhibit activated T cells and macrophages in their pulmonary alveoli.
尽管存在艾滋病毒,但结核分枝杆菌仍具有抵抗力,其肺泡中的 T 细胞和巨噬细胞被激活。
  • DOI:
    10.21203/rs.3.rs-3889020/v1
  • 发表时间:
    2024
  • 期刊:
  • 影响因子:
    0
  • 作者:
    Schurr,Erwin;Dallmann-Sauer,Monica;Fava,Vinicius;Malherbe,Stephanus;McDonald,Candice;Orlova,Marianna;Kroon,Elouise;Cobat,Aurélie;Boisson-Dupuis,Stéphanie;Hoal,Eileen;Abel,Laurent;Möller,Marlo;Casanova,Jean-Laurent;Walzl,Gerhard;
  • 通讯作者:
{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

SABINE EHRT其他文献

SABINE EHRT的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('SABINE EHRT', 18)}}的其他基金

M. tuberculosis carbon metabolism during infection
结核分枝杆菌感染期间的碳代谢
  • 批准号:
    10716619
  • 财政年份:
    2023
  • 资助金额:
    $ 256.5万
  • 项目类别:
Tri-Institutional TRAC Basic Science Core
三机构 TRAC 基础科学核心
  • 批准号:
    10430741
  • 财政年份:
    2022
  • 资助金额:
    $ 256.5万
  • 项目类别:
Tri-Institutional TRAC Basic Science Core
三机构 TRAC 基础科学核心
  • 批准号:
    10675748
  • 财政年份:
    2022
  • 资助金额:
    $ 256.5万
  • 项目类别:
Turning Mycobacterium tuberculosis appetite for fatty acids against itself
结核分枝杆菌对脂肪酸的需求与自身相悖
  • 批准号:
    10592602
  • 财政年份:
    2022
  • 资助金额:
    $ 256.5万
  • 项目类别:
Determinants of TB control, relapse and reinfection
结核病控制、复发和再感染的决定因素
  • 批准号:
    10268801
  • 财政年份:
    2021
  • 资助金额:
    $ 256.5万
  • 项目类别:
Admin Core
管理核心
  • 批准号:
    10268802
  • 财政年份:
    2021
  • 资助金额:
    $ 256.5万
  • 项目类别:
Determinants of Paucibacillary Mtb Infection in Mice
小鼠少杆菌 Mtb 感染的决定因素
  • 批准号:
    10430228
  • 财政年份:
    2021
  • 资助金额:
    $ 256.5万
  • 项目类别:
Determinants of TB control, relapse and reinfection
结核病控制、复发和再感染的决定因素
  • 批准号:
    10430221
  • 财政年份:
    2021
  • 资助金额:
    $ 256.5万
  • 项目类别:
Determinants of Paucibacillary Mtb Infection in Mice
小鼠少杆菌 Mtb 感染的决定因素
  • 批准号:
    10621309
  • 财政年份:
    2021
  • 资助金额:
    $ 256.5万
  • 项目类别:
Determinants of Paucibacillary Mtb Infection in Mice
小鼠少杆菌 Mtb 感染的决定因素
  • 批准号:
    10268807
  • 财政年份:
    2021
  • 资助金额:
    $ 256.5万
  • 项目类别:

相似海外基金

SBIR Phase II: Development of a urine dipstick test that can guide immediate and appropriate antibiotic therapy for treatment of complicated urinary tract infections
SBIR II 期:开发尿液试纸测试,可以指导复杂尿路感染的立即和适当的抗生素治疗
  • 批准号:
    2213034
  • 财政年份:
    2023
  • 资助金额:
    $ 256.5万
  • 项目类别:
    Cooperative Agreement
Personalized Antibiotic Therapy in the Emergency Department: PANTHER Trial
急诊科的个性化抗生素治疗:PANTHER 试验
  • 批准号:
    10645528
  • 财政年份:
    2023
  • 资助金额:
    $ 256.5万
  • 项目类别:
Strategies for improving the efficacy of combinatorial antibiotic therapy in chronic infections
提高慢性感染联合抗生素治疗疗效的策略
  • 批准号:
    10736285
  • 财政年份:
    2023
  • 资助金额:
    $ 256.5万
  • 项目类别:
A Novel Bone Targeted Antibiotic Therapy for the Treatment of Infected Fractures
一种治疗感染性骨折的新型骨靶向抗生素疗法
  • 批准号:
    10603486
  • 财政年份:
    2023
  • 资助金额:
    $ 256.5万
  • 项目类别:
Severe Cutaneous Adverse Reactions Following Outpatient Antibiotic Therapy: A Population-based Study
门诊抗生素治疗后的严重皮肤不良反应:一项基于人群的研究
  • 批准号:
    449379
  • 财政年份:
    2020
  • 资助金额:
    $ 256.5万
  • 项目类别:
    Studentship Programs
Sex-Specific Differences in End-of-Life Burdensome Interventions and Antibiotic Therapy in Nursing Home Residents With Advanced Dementia
患有晚期痴呆症的疗养院居民的临终干预和抗生素治疗的性别差异
  • 批准号:
    422034
  • 财政年份:
    2020
  • 资助金额:
    $ 256.5万
  • 项目类别:
Optimizing outpatient parenteral antibiotic therapy to support hospital-in-the-home program across the unique environmental conditions of Australia
优化门诊肠外抗生素治疗,以支持澳大利亚独特环境条件下的家庭医院计划
  • 批准号:
    nhmrc : 1197866
  • 财政年份:
    2020
  • 资助金额:
    $ 256.5万
  • 项目类别:
    Investigator Grants
Resistance evolution in the presence of combination antibiotic therapy
联合抗生素治疗下耐药性的演变
  • 批准号:
    2241853
  • 财政年份:
    2019
  • 资助金额:
    $ 256.5万
  • 项目类别:
    Studentship
Host-pathogen interactions in antibiotic therapy for listeriosis
李斯特菌病抗生素治疗中宿主与病原体的相互作用
  • 批准号:
    18K07106
  • 财政年份:
    2018
  • 资助金额:
    $ 256.5万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Multipurpose targeted nano-antibiotic therapy to fight tough infection in bones
多用途靶向纳米抗生素疗法可对抗骨骼中的严重感染
  • 批准号:
    9788269
  • 财政年份:
    2018
  • 资助金额:
    $ 256.5万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了